PhaseBio Pharmaceuticals, Inc. (PHAS)
| Market Cap | 39.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 48.69M |
| EPS (ttm) | -2.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,356 |
| Open | 0.880 |
| Previous Close | 0.905 |
| Day's Range | 0.800 - 0.900 |
| 52-Week Range | 0.800 - 4.240 |
| Beta | 2.07 |
| Analysts | Buy |
| Price Target | 14.62 (+1,700.7%) |
| Earnings Date | May 12, 2022 |
About PHAS
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary art...
Analyst Forecast
According to 11 analysts, the average rating for PHAS stock is "Buy." The 12-month stock price forecast is 14.62, which is an increase of 1,700.71% from the latest price.
News
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies f...
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Hig...
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Bentracimab--PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2...
MALVERN, PA & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ACC22--PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at 2022 ACC Annual Scientific Session
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufact...
PhaseBio Provides Pemziviptadil (PB1046) Program Update
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Provides Pemziviptadil (PB1046) Program Update
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #NEJM--PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Names Jonathan Birchall as Chief Commercial Officer
PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study
PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients ...
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplate...
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ti...
PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Prese...
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #AHA2021--PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at AHA Annual Meeting
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentracima...
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Inform...
Do Options Traders Know Something About PhaseBio Pharmaceuticals (PHAS) Stock We Don't?
Investors need to pay close attention to for PhaseBio Pharmaceuticals (PHAS) stock based on the movements in the options market lately.
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at th...
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #AHA21--PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial at Late Breaker at the American Heart Association Scientific Sessions 2021
PhaseBio Appoints William D. Humphries to Board of Directors
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Appoints William D. Humphries to Board of Directors